Discovery of Potent N-Ethylurea Pyrazole Derivatives as Dual Inhibitors of Trypanosoma brucei and Trypanosoma cruzi

Swapna Varghese, Raphael Rahmani, Stephanie Russell, Girdhar Singh Deora, Lori Ferrins, Arthur Toynton, Amy Jones, Melissa Sykes, Albane Kessler, Amanda Eufrásio, Artur Torres Cordeiro, Julian Sherman, Ana Rodriguez, Vicky M. Avery, Matthew J. Piggott, Jonathan B. Baell

Research output: Contribution to journalArticleResearchpeer-review

15 Citations (Scopus)


Trypanosoma brucei (T. brucei) and Trypanosoma cruzi (T. cruzi) are causative agents of parasitic diseases known as human African trypanosomiasis and Chagas disease, respectively. Together, these diseases affect 68 million people around the world. Current treatments are unsatisfactory, frequently associated with intolerable side-effects, and generally inadequate in treating all stages of disease. In this paper, we report the discovery of N-ethylurea pyrazoles that potently and selectively inhibit the viability of T. brucei and T. cruzi. Sharp and logical SAR led to the identification of 54 as the best compound, with an in vitro IC50 of 9 nM and 16 nM against T. b. brucei and T. cruzi, respectively. Compound 54 demonstrates favorable physicochemical properties and was efficacious in a murine model of Chagas disease, leading to undetectable parasitemia within 6 days when CYP metabolism was inhibited.

Original languageEnglish
Pages (from-to)278-285
Number of pages8
JournalACS Medicinal Chemistry Letters
Issue number3
Publication statusPublished - 2020


  • Chagas disease
  • dual inhibitors
  • Human African trypanosomiasis
  • N-ethylurea pyrazole
  • neglected disease

Cite this